Synthesis 2012; 44(18): 2859-2862
DOI: 10.1055/s-0032-1316748
special topic
© Georg Thieme Verlag Stuttgart · New York

Practical Synthesis of 3-Oxa-6-azabicyclo[3.1.1]heptane Hydrotosylate; A Novel Morpholine-Based Building Block

Daniel P. Walker*
Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, MI 49008, USA, Fax: +1(269)4888490   Email: dpwalker@kalexsyn.com
,
Brian M. Eklov
Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, MI 49008, USA, Fax: +1(269)4888490   Email: dpwalker@kalexsyn.com
,
Matthew W. Bedore
Kalexsyn, Inc., 4502 Campus Drive, Kalamazoo, MI 49008, USA, Fax: +1(269)4888490   Email: dpwalker@kalexsyn.com
› Author Affiliations
Further Information

Publication History

Received: 04 June 2012

Accepted: 22 June 2012

Publication Date:
26 July 2012 (eFirst)

Abstract

Bridged bicyclic morpholines are important building blocks in medicinal chemistry research. The bicyclic morpholine 3-oxa-6-azabicylo[3.1.1]heptane (3a) is of particular interest as a morpholine isostere because it is achiral and shows similar lipophilicity to that of morpholine, based on the cLogP of a derived analogue. The first synthesis of morpholine 3a (tosylate salt) is described; the seven-step sequence begins with inexpensive starting materials and uses straightforward chemistry.

Supporting Information

 
  • References

  • 1 Kasper S, El Giamal N, Hilger E. Exp. Opin. Pharmacother. 2000; 1: 771
  • 2 Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR. J. Med. Chem. 2008; 51: 1981
    • 3a Wasson BK, Gibson WK, Stuart RS, Williams HW. R, Yates CH. J. Med. Chem. 1972; 15: 651
    • 3b Mazzo DJ, Loper AE. Analytical Profiles of Drug Substances 1987; 16: 641
  • 4 Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L. Bioorg. Med. Chem. Lett. 2001; 1911
    • 5a Griffin RJ, Fontana G, Golding BT, Guiard S, Hardcastle IR, Leahy JJ. J, Martin N, Richardson C, Rigoreau L, Stockley M, Smith GC. M. J. Med. Chem. 2005; 48: 569
    • 5b Blizzard TB, DiNinno F, Morgan JD. II, Chen HY, Wu JY, Gude C, Kim S, Chan W, Birzin ET, Yang YT, Pai L.-Y, Zhang Z, Hayes EC, DaSilva CA, Tang W, Rohrer SP, Schaeffer JM, Hammond ML. Bioorg. Med. Chem. Lett. 2004; 3861
    • 5c Roecker AJ, Coleman PJ, Mercer SP, Schreier SD, Buser CA, Walsh ES, Hamilton K, Lobell RB, Tao W, Diehl RE, South VJ, Davide JP, Kohl NE, Yan Y, Kuo LC, Li C, Fernandez-Metzler C, Mahan EA, Prueksaritanont T, Hartman GD. Bioorg. Med. Chem. Lett. 2007; 5677
    • 5d Venkatesan AM, Chen Z, Santos OD, Dehnhardt C, Santos ED, Ayral-Kaloustian S, Mallon R, Hollander I, Feldberg L, Lucas J, Yu K, Chaudhary I, Mansour TS. Bioorg. Med. Chem. Lett. 2010; 5869
    • 5e Zask A, Kaplan J, Verheijen JC, Richard DJ, Curran K, Brooijmans N, Bennett EM, Toral-Barza L, Hollander I, Ayral-Kaloustian S, Yu K. J. Med. Chem. 2009; 52: 7942
    • 5f Tsuo H.-R, MacEwan G, Birnberg G, Zhang N, Brooijmans N, Toral-Barza L, Hollander I, Ayral-Kaloustian S, Yu K. Bioorg. Med. Chem. Lett. 2010; 2259
  • 6 Wuitschik G, Carreira EM, Wagner B, Fischer H, Parrilla I, Schuler F, Rogers-Evans M, Müller K. J. Med. Chem. 2010; 53: 3227
  • 7 Ding Y, Liu W, Lu C, Yang J, Zhu Y, Song Y, Ma Z, Yang L, Jia Y, Wen A. Biomed. Pharmacother. 2012; 66: 98
  • 8 Verheijen JC, Yu K, Toral-Barza L, Hollander I, Zask A. Bioorg. Med. Chem. Lett. 2010; 375
    • 9a Newth FH, Wiggins LF. J. Chem. Soc. 1948; 155
    • 9b Connolly TJ, Considine JL, Ding Z, Forsatz B, Jennings MN, MacEwan MF, McCoy KM, Place DW, Sharma A, Sutherland K. Org. Process Res. Dev. 2010; 14: 459
    • 10a v. Braun J, Leistner W. Ber. Dtsch. Chem. Ges. 1926; 59: 2323
    • 10b Axten JM, Brady Jr GP., Gallagher TF, Heerding DA, Medina JR, Romeril SP. Patent Cooperation Treaty WO 2010/120854, 2010 ; Chem. Abstr. 2010, 153, 555216.
  • 11 Portoghese PS, Turcotte JG. J. Med. Chem. 1971; 14: 288
  • 12 Flohr A, Jakob-Roetne R, Norcross RD, Riemer C. Patent Cooperation Treaty WO 2003/049741, 2003 ; Chem. Abstr. 2003, 139, 53026.
  • 13 Wishka DG, Beagley P, Lyon J, Farley KA, Walker DP. Synthesis 2011; 2619
  • 14 Guanti G, Riva R. Tetrahedron: Asymmetry 2001; 12: 605
  • 15 Kozikowski AP, Tückmantel W, Reynolds IJ, Wroblewski JT. J. Med. Chem. 1990; 33: 1561
  • 16 Kozikowski has used similar conditions to effect the isomerization of a related substrate, see ref. 15.
  • 17 Wasserman HH, Han WT, Schaus JM, Faller JW. Tetrahedron Lett. 1984; 3111
  • 18 Evans GB, Furneaux RH, Greatrex B, Murkin AS, Schramm VL, Tyler PC. J. Med. Chem. 2008; 51: 948
  • 19 Similar conditions were used to effect ether ring formation on a related 3-oxa-8-azabicyclo[3.2.1]octane system, see: Chen Z, Venkatesan AM, Santos OD, Santos ED, Dehnhardt CM, Ayral-Kaloustian S, Ashcroft J, McDonald LA, Mansour TS. J. Org. Chem. 2010; 75: 1643